ABSTRACT
There are no definite tumor markers for ICC, although carcinoembryonic antigen (CEA) and carbohydrate antigen
Intrahepatic cholangiocarcinoma (ICC) is a rare ( 1 , 2 ) and poorly understood biliary malignancy that is increasing in incidence and therefore, in importance. The literature concerning this disease is mostly limited to retrospective reviews of patients from specialized hepatobiliary centers; moreover, only a few case series have included 50 or more patients ( 3-6 ). Surgical resection has offered the only chance of cure in patients since the earliest era ( 7 ). However, no consensus or guidelines have been established on the optimum procedure in accordance with the stage of the disease. This article is a review of the current knowledge on intrahepatic cholangiocarcinoma, especially from the viewpoint of experienced liver surgeons who treat it.
